Citadel Advisors
VIRX

Citadel Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Citadel Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-400
Closed -$217 – 15510
2024
Q2 		$217 Buy
+400
New +$316 ﹤0.01% 14065
2024
Q1 		– Sell
-400
Closed -$228 – 15627
2023
Q4 		$228 Hold
400
– – ﹤0.01% 14085
2023
Q3 		$416 Sell
400
-1,300
-76% -$1.76K ﹤0.01% 14061
2023
Q2 		$2.4K Sell
1,700
-200
-11% -$286 ﹤0.01% 13786
2023
Q1 		$3.02K Sell
1,900
-2,500
-57% -$4.54K ﹤0.01% 14080
2022
Q4 		$6.42K Sell
4,400
-21,300
-83% -$62.2K ﹤0.01% 13920
2022
Q3 		$110K Sell
25,700
-4,100
-14% -$17.4K ﹤0.01% 11006
2022
Q2 		$116K Buy
29,800
+1,900
+7% +$5.41K ﹤0.01% 11267
2022
Q1 		$133K Sell
27,900
-10,872
-28% -$32.8K ﹤0.01% 11985
2021
Q4 		$142K Buy
38,772
+288
+0.7% +$1.54K ﹤0.01% 12338
2021
Q3 		$309K Sell
38,484
-4,832
-11% -$47.6K ﹤0.01% 11020
2021
Q2 		$491K Sell
43,316
-254
-0.6% -$2.55K ﹤0.01% 10105
2021
Q1 		$403K Buy
+43,570
New +$454K ﹤0.01% 10162
2020
Q3 		– Sell
-1,037
Closed -$10K – 10885
2020
Q2 		$10K Sell
1,037
-46
-4% -$693 ﹤0.01% 9638
2020
Q1 		$16K Buy
1,083
+700
+183% +$15.2K ﹤0.01% 9349
2019
Q4 		$5K Hold
383
– – ﹤0.01% 9021
2019
Q3 		$10K Buy
+383
New +$11.1K ﹤0.01% 9042
2018
Q3 		– Sell
-494
Closed -$37K – 9806
2018
Q2 		$37K Buy
+494
New +$44K ﹤0.01% 8503
2016
Q1 		– Sell
-46
Closed -$9K – 8177
2015
Q4 		$9K Sell
46
-15
-25% -$2.81K ﹤0.01% 8313
2015
Q3 		$10K Sell
61
-28
-31% -$10.1K ﹤0.01% 8475
2015
Q2 		$56K Buy
89
+9
+11% +$4.78K ﹤0.01% 7584
2015
Q1 		$41K Buy
80
+70
+700% +$35.3K ﹤0.01% 7515
2014
Q4 		$5K Sell
10
-185
-95% -$83.4K ﹤0.01% 8277
2014
Q3 		$293K Buy
195
+150
+333% +$217K ﹤0.01% 5285
2014
Q2 		$62K Buy
45
+16
+55% +$18.6K ﹤0.01% 6606
2014
Q1 		$40K Buy
+29
New +$33.7K ﹤0.01% 6919

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Citadel Advisors's VIRX Position: Q1 2025 in Review

Citadel Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 1,626,258 shares — an estimated $262K sold.

Citadel Advisors first reported a position in VIRX in Q1 2014 and held it in 35 quarters. The position peaked at $23.3M in Q3 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Citadel Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,626,258 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $262K.
  • Citadel Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 35 quarters.
  • Citadel Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $23.3M in Q3 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.